We report on latest developments of our company and its pipeline. For details and media inquiries please get in touch with us.
ORYX to attend CIMT 2024
We will attend CIMT Annual Meeting 2024, taking place between May 15-17 in Mainz, Germany. A poster presentation (No. 127, Session II) and a talk session (Short Talk Session VI) will be held by one of our clinicians about "Pattern of tumor regression of recurrent glioblastoma after intratumoral virus injection of oncolytic parvovirus H-1 strongly supports virus contribution in effective viro-immunotherapy". We are looking forward to meeting you!
New Website launched
We have launched a new website: Besides technical upgrades and design changes reflecting ORYX' innovative and dynamic approach to fight cancer, clinical data have been updated. Feel free to give us feedback!
Prof. Dr. zur Hausen passed away
It is with great sadness that we have to announce that Prof. Dr. Harald zur Hausen, one of our Senior Advisors, has passed away at the age of 87. Harald was an extraordinary person who dedicated his life to the fight against cancer. His research created, among other things, the basis for the development of a vaccine against HPV-associated cancers that today benefits millions of people around the world. The highlight of his career was the award of the Nobel Prize in Medicine in 2008. Harald will be missed both personally and professionally.
Article about ParvOryx published online in peer-reviewed Appl. Microbiol. Biotechnol.
The article "Stability and safety key factors of the oncolytic protoparvovirus H-1 from manufacturing to human application" by German Cancer Research Center's Tumor Virology Team has been published online in peer-reviewed Applied Microbiology and Biotechnology. It focusses on the stability and environmental safety of ParvOryx from manufacturing up to its use in patients, including hold-stops in manufacturing, stability, stress testing and de- and rehydration for lyophilization simulation.
ORYX attends CIMT Meeting in Mainz
We will participate in the 20th Europe's Cancer Immunotherapy Meeting in Mainz, Germany, which will be held May 3-5, 2023. In addition to discussions with pharma partners, a team of our partners will present data on CAR-T cell therapies in combination with ParvOryx in a Human Tumor Explant Model model during a poster session.
© 2024 — Oryx GmbH & Co. KG
We take the protection of your data seriously. This is why we let you decide about the use of our analytics cookies. See our Privacy Policy to learn more about our analytics cookies.